Palvella Therapeutics (NASDAQ:PVLA) Earns “Buy” Rating from BTIG Research

Palvella Therapeutics (NASDAQ:PVLA)‘s stock had its “buy” rating reissued by analysts at BTIG Research in a note issued to investors on Thursday,Benzinga reports. They currently have a $192.00 price target on the stock. BTIG Research’s price target would suggest a potential upside of 143.93% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. Truist Financial upped their target price on Palvella Therapeutics from $105.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Chardan Capital boosted their price target on Palvella Therapeutics from $110.00 to $174.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Oppenheimer restated an “outperform” rating and issued a $200.00 price target on shares of Palvella Therapeutics in a report on Monday, December 15th. TD Cowen reaffirmed a “buy” rating on shares of Palvella Therapeutics in a research report on Tuesday, December 16th. Finally, Mizuho began coverage on shares of Palvella Therapeutics in a research note on Wednesday, January 7th. They set an “outperform” rating and a $205.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Palvella Therapeutics currently has an average rating of “Buy” and a consensus target price of $158.69.

Palvella Therapeutics Stock Down 6.3%

Palvella Therapeutics stock opened at $78.71 on Thursday. The firm has a fifty day moving average of $97.13 and a 200-day moving average of $71.89. Palvella Therapeutics has a 52-week low of $12.48 and a 52-week high of $114.69. The firm has a market capitalization of $931.93 million, a P/E ratio of -29.93 and a beta of -0.16.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). On average, research analysts expect that Palvella Therapeutics will post -3.69 EPS for the current fiscal year.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total value of $420,004.26. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders sold 12,906 shares of company stock worth $1,205,980. 20.50% of the stock is owned by insiders.

Institutional Trading of Palvella Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in PVLA. Archer Investment Corp acquired a new stake in Palvella Therapeutics in the third quarter valued at $28,000. Bank of America Corp DE raised its stake in shares of Palvella Therapeutics by 12.3% in the 3rd quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock valued at $294,000 after purchasing an additional 515 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Palvella Therapeutics in the 3rd quarter valued at about $36,000. JPMorgan Chase & Co. lifted its position in shares of Palvella Therapeutics by 33.7% during the third quarter. JPMorgan Chase & Co. now owns 4,338 shares of the company’s stock worth $272,000 after purchasing an additional 1,093 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Palvella Therapeutics in the fourth quarter worth about $167,000. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.